logo
Trump news at a glance: president's ‘big, beautiful bill' clears first Senate hurdle

Trump news at a glance: president's ‘big, beautiful bill' clears first Senate hurdle

Yahoo19 hours ago

After a scramble in the Senate, Republicans voted on Saturday to advance Trump's signature 'big, beautiful' bill, with a 51-49 vote.
Republicans had been divided over the controversial bill, with some rejecting the proposal to cut welfare programmes in order to cover tax breaks, and others demanding deeper cuts.
The key procedural hurdle was cleared hours after the debate opened, with two Republicans, senators Thom Tillis of North Carolina and Rand Paul of Kentucky, voting with Democrats to block consideration of the measure.
Meanwhile, the tech billionaire Elon Musk again voiced criticism of bill, describing it as 'utterly insane and destructive'.
Here are the key stories at a glance:
The Republican-controlled US Senate advanced president Donald Trump's sweeping tax-cut and spending bill in a key procedural vote on Saturday, raising the odds that lawmakers will be able to pass the legislation in coming days.
Read the full story
The billionaire tech entrepreneur Elon Musk on Saturday criticized the latest version of Donald Trump's sprawling tax and spending bill, calling it 'utterly insane and destructive'.
'The latest Senate draft bill will destroy millions of jobs in America and cause immense strategic harm to our country!' Musk wrote on Saturday.
Read the full story
The Democratic former Minnesota state house speaker Melissa Hortman was honored for her legislative accomplishments and her humanity during a funeral on Saturday that was attended by Joe Biden and Kamala Harris.
The former president and vice-president were joined by more than 1,000 other mourners.
Read the full story
Eric Trump has hinted that he or another of the Trump family could run for president when his father's second term in the White House comes to an end.
Eric, who is co-executive vice-president of the Trump Organization, said, the road to the White House 'would be an easy one' if he decided to follow in his father's footsteps.
Read the full story
Police in southern California arrested a man suspected of posing as a federal immigration officer this week, the latest in a series of such arrests, as masked, plainclothes immigration agents are deployed nationwide to meet the Trump administration's mass deportation targets.
Read the full story
The son of an American citizen and military veteran – but who has no citizenship to any country – was deported from the US to Jamaica in late May.
Jermaine Thomas's deportation, recently reported on by the Austin Chronicle, is one of a growing number of immigration cases involving military service members' relatives or even veterans themselves who have been ensnared in the Trump administration's mass deportation program.
Read the full story
Two men face spending their lives in prison after a federal judge sentenced them for their roles in the deaths of 53 people found dead in an abandoned tractor-trailer in Texas in 2022.
The sudden loss of key US satellite data could send hurricane forecasting back 'decades', scientists say.
Mark Zuckerberg's secret list of top AI talent to poach has the tech world atwitter.
Catching up? Here's what happened on .

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Citi Maintains ‘Neutral' Rating on EchoStar Corporation (SATS); Raises PT
Citi Maintains ‘Neutral' Rating on EchoStar Corporation (SATS); Raises PT

Yahoo

time29 minutes ago

  • Yahoo

Citi Maintains ‘Neutral' Rating on EchoStar Corporation (SATS); Raises PT

EchoStar Corporation (NASDAQ:SATS) is one of the best stocks for a . The corporate headquarters of a satellite radio systems company, illuminating the skyline. As announced on June 24, 2025, Citi maintained a 'Neutral' rating on EchoStar Corporation (NASDAQ:SATS), raising its price target from $27 to $28.50. The analyst cited its reevaluation of EchoStar's potential value related to its spectrum assets. These assets include the company's licenses for radio frequencies used for communication. Furthermore, Citi expects a strategic update to be announced by the company within 30 days. The analyst highlights its importance as this expected development would come at a critical time, as EchoStar approaches a bond-related interest payment milestone. EchoStar Corporation (NASDAQ:SATS), a U.S.-based telecommunications company, delivers broadband, wireless, and satellite services through its Pay-TV, Retail Wireless, and BSS segments, and is also part of our growth stock portfolio. While we acknowledge the potential of SATS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: 10 Overlooked Tech Stocks to Buy Now and 10 Low Risk High Reward Stocks Set to Triple by 2030. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BMO Capital Maintains ‘Outperform' Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT
BMO Capital Maintains ‘Outperform' Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT

Yahoo

time29 minutes ago

  • Yahoo

BMO Capital Maintains ‘Outperform' Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best stocks added in a . A well-stocked pharmacy shelf full of the company's pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products. BMO Capital maintained an 'Outperform' rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), announcing this on June 24, 2025. The analyst raised its price target on the company's stock from $300 to $360. BMO Capital attributed this update to a drastic increase in Amvuttra sales for ATTR-CM, according to IQVIA tracking data, after the drug's approval in March. Furthermore, the analyst cited the continued consistency of the company's sales trends, reinforcing confidence in its commercial traction. While short-term skepticism exists regarding the company's revenue growth, Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) consistent historical trend of revenue and pipeline growth supports its potential for continued growth. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a biopharmaceutical company, develops and markets RNAi therapeutics for rare and genetic diseases. The company has demonstrated consistent YoY revenue growth, making it part of the growth stock portfolio. While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: 10 Best Marketing Stocks to Buy Right Now and 10 Best Cybersecurity Stocks to Invest in Under $20. Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store